Standards & Regulation

The first Humira biosimilar in the US is here, but market penetration could be a challenge.

New technologies offer cheaper modes of manufacture – here’s how and why the world’s less wealthy countries could seize the moment.

Anti-vaccine activists are suing a number of prominent media outlets, including Reuters, the Washington Post, the BBC, and the Associated Press.

What can cell and gene do to avoid a seemingly inevitable rush on supporting products and services?

Why critical starting materials are crucial to the production of cell and gene therapies, and among them cord blood deserves particular attention

In the face of economic uncertainty in a post-pandemic world, how will the cell and gene field respond?

Get a sharp perspective on the cell and gene status quo in The Medicine Maker 2022 supplement on advanced medicine

After years of progress in the courts, could one verdict in California give unproven stem cell clinics an unwelcome boost?

How a new working group plans to overcome the problem with in vitro pharmacology data.

Unregulated drugs being sold and distributed by the online retailer come under fire.